ReviewJournal of hepatocellular carcinoma2026
Histone Methylation: A Pivotal Epigenetic Driver of the Malignant Transformation of MASLD-HCC.
Review in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is characterized by high invasiveness and drug resistance, resulting in a generally poor prognosis for patients. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and its advanced form, Metabolic Dysfunction-Associated Steatohepatitis (MASH), are important precancerous lesions of HCC. Interventions during the critical precancerous stage before the occurrence of HCC have been recognized as a core strategy to improve prognosis. However, the key mechanisms driving the malignant transformation of MASLD/MASH to HCC remain incompletely elucidated. Among the multifaceted landscape of epigenetic alterations, histone methylation constitutes a dynamic and reversible regulatory layer uniquely positioned to couple metabolic stress with aberrant gene expression. Precisely governed by "writers", "erasers", and "readers", this modification serves as a crucial epigenetic checkpoint in the transition from benign steatosis to malignancy. A central unanswered question is which epigenetic sensors translate the metabolic milieu of MASLD/MASH into stable transcriptional reprogramming, and specifically how histone methylation dynamics govern the transition from reversible steatosis to irreversible malignancy. Increasing evidence suggests that abnormal histone methylation modifications are not only closely associated with the occurrence and development of HCC but may also dominate the transformation process from MASLD/MASH to early HCC, making them highly promising predictive biomarkers and therapeutic targets. This review summarises the molecular mechanisms of histone methylation modifications in the malignant transformation and progression of MASLD/MASH to HCC, to provide new epigenetic insights and potential targets for early intervention and treatment of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.